Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19
NCT ID: NCT04496141
Last Updated: 2024-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
70 participants
OBSERVATIONAL
2020-07-27
2020-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year
NCT04910971
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
NCT04898946
Community-based Sero-epidemiological Study of COVID-19
NCT05599555
The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic
NCT04416061
A Study to Evaluate Vaccines Against COVID-19 in the Real World
NCT04775056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The test results are then compared and analyzed with statistical tests to assess the immunoassays'performance
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
With COVID-19 infection
Subjects with a positive SARS-CoV-2 PCR
SARS-CoV-2 antibody immunoassays
Different commercial SARS-CoV-2 antibody immunoassays
Without COVID-19 infection
Subjects with COVID-19 negative serum
SARS-CoV-2 antibody immunoassays
Different commercial SARS-CoV-2 antibody immunoassays
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SARS-CoV-2 antibody immunoassays
Different commercial SARS-CoV-2 antibody immunoassays
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hong Kong Sanatorium & Hospital
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Jonpaul ST Zee
Specialist in Infectious Disease
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonpaul Sze Tsing Zee, MBChB
Role: PRINCIPAL_INVESTIGATOR
Hong Kong Sanatorium & Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hong Kong Sanatorium & Hospital
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC-2020-12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.